target downgrad unit state go sg websit
upsid tp
nc chang
surpris bm heavili penalis plan divest
otezla psoriasi consumm celgen acquisit stock
day june think decis signal improv
product impli celgen phase psoriasi
larger npv acknowledg same-day announc setback
immunotherapi opdivo unhelp remain convinc ex us
post-surg opportun field underestim addit
outli valuat see chart bottom still think market continu
ignor increas option celgen offer moreov unlik
pharma transform stori forecast sustain dividend growth bm
chang cut pro forma ep forecast reflect
otezla divest plan failur opdivo cancer immunotherapi treatment
nave liver cancer checkmat howev still assum celgen
deal close januari earn pro forma entiti start
declin henc input manag guidanc still target continu
pro forma top- bottom-lin growth impli upsid net
valu stock tp still base simpl averag short-term
multipl dcf appropri captur group short- long-term prospect
near term continu valu bm pariti sector forecast growth
least line global sector averag wacc perpetu growth
assumpt also unchang trim tp lower
earn estim revis tp impli trough discount global peer
think adequ reflect bmss long-term challeng ad dividend
impli tsr buy note input manag guidanc model
would trigger sector mean revers valuat els equal
could wrong three largest downsid risk pro forma
ebita forecast would opdivo cancer immunotherapi flatlin vs
compound-annual-growth-rate due increas competit eliqui anticoagul
flatlin vs compound-annual-growth-rate due price competit headwind
celgen entir phase pipelin fail
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor make
invest decis pleas appendix end report analyst certif import
squibb corpor found brooklyn new york edward robinson
squibb john ripley myer william mclaren bristol acquir clinton
decid renam bristol myer compani two
compani merg creat bristol myer squibb bm bm acquir
medarex part string pearl strategi allianc partnership acquisit
medarex key asset immunotherapi io drug opdivo bmss import
growth driver see tabl dr giovanni caforio chairman ceo sinc
januari compani announc intent acquir us biotech compani
celgen n/r cash stock deal approv set
sharehold april
product relev invest debat
develop medarex ono
us book sale co-market us
us volum limit gener competit
enter celgen pipelin via acquisit recepto
reason
reason
sg forecast pro forma sale ep contract everi year
forma dcf current share price
progress dividend polici post equiti issuanc celgen sharehold product concentr risk still high post celgen integr
share price under-perform
june bristol myer squibb bm announc plan divest otezla
celgen product treat psoriasi psoriat arthriti autoimmun diseas order
facilit anti-trust clearanc propos acquisit celgen unrat bm
simultan indic expect acquisit close earli
earlier marker previous indic
day bm also indic phase checkmat trial fail prove
cancer immunotherapi opdivo effect nexavar bayer/onyx
sale patient treatment nave late stage liver cancer
announc trigger fall bm share price day
what view
recap celgen launch otezla drug achiev revenu
growth understand celgen investor relat ir drug unlik
face gener competit
view highest profil pipelin drug stand-alone
phase trial psoriasi understand bm ir studi
power show superior activ compar otezla tyrosin new
class tablet-bas drug develop address auto-immun diseas psoriasi
potenti better toler exist oral therapi like otezla xeljanz
jak inhibitor consensu sale estim see quot
select allow target specif cytokin
pathway type interferon
implic psoriasi absenc neutropenia elev liver enzym level
serum creatinin level dyslipidemia advers effect
observ clinic trial jak inhibitor target similar cytokin consist
differ activ two class drug
sourc phase data peer review new england journal medicin octob
prior news describ carri sale pro forma model
assum would divest consumm celgen deal howev
care consider believ bm made right decis sell otezla retain
view bmss clinic develop programm suggest bms-
activ could much broader otezla tabl also note bms-
first-mov advantag categori tabl
calcul npv otezla equival sale believ drug
highli profit addit despit increas competit believ continu
grow patent expiri view compani global pharma coverag univers
could interest purchas asset bolster immuno-inflamm
franchis order prioriti johnson johnson sanofi novarti
moder sever plaqu
moder sever plaqu
phase moder sever plaqu
ultra high risk
ultra high risk
ultra high risk
ultra high risk
immunotherapi chang estim
recap bm would enjoy first-mov advantag
studi success therefor cut opdivo forecast
acknowledg investor concern whether immunotherapi growth
franchis bm month howev although forecast declin opdivo
sale still expect product grow thereaft potenti outsid
us chart left adjuv earli post-surgeri set
opdivo revenu geographi bn sg new estim
opdivo yervoy global revenu indic bn sg new
previou pro forma ep forecast alreadi assum celgen acquisit would
consumm januari howev cut pro forma net incom forecast tabl
reflect follow
-- divest otezla decemb npv
-- -- remov opdivo sale
first-tim inclus forecast risk-adjust
sale
non-gaap net incom chang sg estim
recap result bm indic follow closur celgen deal
target pro forma sale net incom grow everi year manag
reiter guidanc despit neg news describ input guidanc
model impli upsid net incom forecast
alway base target price unweight averag three-year forward ev/ebita
multipl dcf automat take account stock short- long-term growth
prospect lower bm target price chang forecast describ
new target price still impli trough discount global pharma peer
moreov input manag guidanc model impli share price
stock revert sector mean price-to-earnings ep growth regress plot
assum pariti sector
assum wacc perpetu growth
premium/discount sector
matur product
product sold
net earn attribut sharehold
total liabil equiti
chang work capit
flow oper activ
flow invest activ
net chang debt
proce issue/buyback share
flow financ activ
effect foreign exchang
net chang cash/cash equival
begin year
year-end
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
share basic year end/outstand
share price average hist yr current
report complet jun cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report justin smith
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan geneva seoul warsaw moscow
alway base target price unweight averag sotp use three-year forward ev/ebita multipl dcf
automat take account stock short- long-term growth prospect sotp valu pariti sector
ev/ebitda dcf assum wacc termin growth rate
three largest downsid risk pro-forma ebita forecast would opdivo cancer immunotherapi flatlin vs compound-annual-growth-rate
eliqui anticoagul flatlin vs compound-annual-growth-rate celgen
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
equiti rate dispers relationship
updat
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin use
creat financi product includ indic inform provid basi user assum entir risk
use made inform affili third parti involv relat comput compil inform
herebi expressli disclaim warranti origin accuraci complet merchant fit particular purpos
respect inform without limit forego event shall affili third parti involv
relat comput compil inform liabil damag kind morgan stanley capit
index servic mark affili similar languag may provid approv
advanc
